Pirfenidone, an Antifibrotic and Antiinflammatory Drug for Treatment of Patients With Cirrhosis Due to Hepatitis C Virus. Phase II/III Study

NCT02161952 Phase 2 COMPLETED

The aim of this study was to assess whether two-year treatment with Pirfenidone influence necro-inflammation, fibrosis and steatosis in patients with chronic hepatitis C.

Details

Lead sponsor	University of Guadalajara
Phase	Phase 2
Status	COMPLETED
Enrolment	150
Start date	2005-05
Completion	2007-08

Conditions

• Fibrosis
• Hepatitis C Chronic

Interventions

• Pirfenidone
• Matched equivalent placebo

Primary outcomes

• Fibrosis staging — 24 months
  Fibrosis was evaluated according to Ishak fibrosis staging scale.